Economic Moat
INVESTOR
Capital Allocation
INVESTOR
CureVac is making progress across its early-stage mRNA pipeline. The company reported first-quarter revenue of EUR 7.1 million, of which revenue from its GSK collaboration agreement accounted for EUR 6.5 million. We maintain CureVac's fair value estimate of $15.40 per share, a no-moat rating, stable moat trend, and Extreme Morningstar Uncertainty Rating. The stock is trading at an attractive discount to our fair value estimate for long-term investors.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of CVAC’s competitive advantage.
CureVac NV Ordinary Shares
XNAS: CVAC
| United Therapeutics Corp
XNAS: UTHR
| Moderna Inc
XNAS: MRNA
| BioNTech SE ADR
XNAS: BNTX
| |
Price
| 9.71 | 228.49 | 123.26 | 109.25 |
Currency
| USD | USD | USD | USD |
Change
| −$0.79 (7.52%) | +$1.99 (0.88%) | −$1.68 (1.34%) | +$0.28 (0.26%) |
Market Cap
| 2.17 Bil | 10.71 Bil | 46.99 Bil | 26.33 Bil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
No. CVAC does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
CVAC’s market cap is 2.17 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
CVAC’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
CVAC’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare CVAC’s historical performance against its industry peers and the overall market.
